Edge Therapeutics

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops, and seeks to commercialize novel, hospital-based therapies capable of transforming the treatment of life-threatening acute neurological conditions. EG-1962, our lead product candidate, has the potential to fundamentally improve patient outcomes and change the management of aneurysmal subarachnoid hemorrhage (aSAH), a condition involving bleeding around the brain caused by a ruptured cerebral aneurysm. EG-1964, our second product candidate, is being evaluated as a potential prophylactic treatment for chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain.